Latest Breaking News On - Stephena harrison - Page 8 : comparemela.com

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesLyudmila matevaRohit loombaNicolas lanthierSven francqueStephena harrisonLuisa vonghiaMarie paule richardDiana stefanova petrovaManalf abdelmalekYannick tetzlaffMartine baudinArunj sanyalNaim alkhouriAude lepreux

Altimmune to Host Key Opinion Leader Call with Dr Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021

Altimmune to Host Key Opinion Leader Call with Dr Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesSan antonioBrooke army medical centerStephena harrisonSaint louis universityUnited states armyAltimmune incUniversity of oxfordArmy surgeon generalUniversity of mississippi school medicineRadcliffe department of medicinePinnacle clinical researchUniformed services university of the health sciencesEducation at brooke army medical centerSummit clinical researchMississippi school

Altimmune to Host Key Opinion Leader Call with Dr Stephen Harrison on Pemvidutide Phase 1

Altimmune to Host Key Opinion Leader Call with Dr Stephen Harrison on Pemvidutide Phase 1
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioBrooke army medical centerStephena harrisonSaint louis universityUnited states armyAltimmune incUniversity of oxfordArmy surgeon generalUniversity of mississippi school medicineRadcliffe department of medicinePinnacle clinical researchUniformed services university of the health sciencesMd pinnacle clinical researchEducation at brooke army medical centerSummit clinical research

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJacky vonderscherStephena harrisonKostenloser wertpapierhandelPietro scalfaroAnnie florence loyerPinnacle clinical researchFrench infectiology research centerAlcoholic steato hepatitisPrincipal investigatorMedical directorPinnacle clinicalChief executive officerNon alcoholic steato hepatitisBile acidFlorence loyer

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125 Initial clinical sites activated and patient screening underway Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH) CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH. “NASH is the quintessential complex disease, involving the dysregulation of numerous biological pathways and impacting an enormous, heterogenous global population,” said Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visi

United statesUnited kingdomSan antonioAlison schecterStephena harrisonPinnacle clinical researchUniversity of oxfordDrug administrationGlobal liver instituteMedical directorBill hinshawChief executive officerNon alcoholic steatohepatitisEndogenous metabolic modulatorsPrivate securities litigation reform actAnnual report